Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...

The Colts haven't won in Jacksonville since 2014, and this loss is critical in the AFC playoff race. Riley Leonard is the Colts' quarterback after Daniel Jones leaves with an injury. Everything looks ...

Manchester City trimmed Arsenal's lead at the top of the Premier League table to two points with a 3-0 win over Sunderland at the Etihad. The Gunners were beaten 2-1 by Aston Villa in the lunchtime ...

At Ford Field on Thursday, Amon-Ra St. Brown and the Detroit Lions (7-5) face Javonte Williams and the Dallas Cowboys (6-5-1) in a matchup featuring two of the brightest stars in the NFL, beginning at ...

If you're in the market for a new car, you’ve probably come across terms like MSRP and invoice price. Both terms are used to describe the cost of a vehicle, but there are a few key differences.

Cytokinetics, Incorporated's (CYTK) shares surged 40.4% on Sept. 2, driven by positive results from a phase III study on cardiovascular candidate aficamten. On Aug. 30, Cytokinetics presented primary ...

Data from the late-stage MAPLE-HCM study position Cytokinetics’ cardiac myosin inhibitor aficamten as a potential first-line therapy for patients with obstructive hypertrophic cardiomyopathy.

During a medical event on Saturday, Cytokinetics (NASDAQ:CYTK) announced primary results from its Phase 3 MAPLE-HCM trial for lead asset aficamten in symptomatic obstructive hypertrophic ...

(RTTNews) - Cytokinetics, Incorporated (CYTK), Tuesday announced positive topline results from Phase 3 MAPLE-HCM study of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy ...

Trial Demonstrates Superiority of Aficamten to Standard of Care Beta Blocker in Improving Peak Exercise Capacity in Patients with Obstructive Hypertrophic Cardiomyopathy The full results from ...

The U.S. Food and Drug Administration (FDA) on Thursday extended the Prescription Drug User Fee Act (PDUFA) action date for the New Drug Application (NDA) for Cytokinetics Inc's (NASDAQ:CYTK) ...